Roswell Park Cancer Institute (RPCI; Buffalo, New York) is taking a more tailored approach with cancer therapy through the formation of its spin-out company, OmniSeq (also Buffalo). The company, which is fueled by $20 million worth of funding from RPCI, will focus on a collaborative approach to genomic diagnostics – matching cancer patients to specifically tailored therapies. Initially the company will focus on lung cancer. Read More
